Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

被引：4
|
作者：
Duerr, Donat [1 ]
Siciliano, Raffaele Daniele [1 ]
Hummel, Yvonne [1 ]
O'Meara, Alix [1 ]
Hirschi, Anita [1 ]
Burkhard, Roger [1 ]
Honegger, Hanspeter [1 ]
机构：
[1] Stadtspital Triemli, CH-8063 Zurich, Switzerland
来源：
ANNALS OF HEMATOLOGY | 2010年 / 89卷 / 01期
关键词：
DELETION; MANAGEMENT; DEL(5Q);
D O I：
10.1007/s00277-009-0775-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [41] Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment
    Krejcik, Zdenek
    Belickova, Monika
    Hrustincova, Andrea
    Klema, Jiri
    Zemanova, Zuzana
    Michalova, Kyra
    Cermak, Jaroslav
    Jonasova, Anna
    Merkerova, Michaela Dostalova
    CANCER GENETICS, 2015, 208 (04) : 156 - 161
  • [42] Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
    Ekaterina Balaian
    Claudia Schuster
    Claudia Schönefeldt
    Ulrich Germing
    Detlef Haase
    Sebastian Tuve
    Rainer Ordemann
    Gerhard Ehninger
    Martin Bornhäuser
    Uta Oelschlaegel
    Brigitte Mohr
    Malte von Bonin
    Uwe Platzbecker
    Martin Wermke
    Annals of Hematology, 2016, 95 : 1805 - 1810
  • [43] Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment
    Knop, Stefan
    Einsele, Hermann
    Bargou, Ralf
    Cosgrove, Denise
    List, Alan
    LEUKEMIA & LYMPHOMA, 2008, 49 (02) : 346 - 349
  • [44] Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q
    Balaian, Ekaterina
    Schuster, Claudia
    Schoenefeldt, Claudia
    Germing, Ulrich
    Haase, Detlef
    Tuve, Sebastian
    Ordemann, Rainer
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Oelschlaegel, Uta
    Mohr, Brigitte
    von Bonin, Malte
    Platzbecker, Uwe
    Wermke, Martin
    ANNALS OF HEMATOLOGY, 2016, 95 (11) : 1805 - 1810
  • [45] A PATIENT WITH MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q) AND IRON OVERLOAD TREATED WITH LENALIDOMIDE AND DEFERASIROX: A CASE REPORT
    Guaragna, G.
    Rinaldi, E.
    Girasoli, M.
    Spina, A.
    Mele, G.
    Quarta, G.
    Melpignano, A.
    HAEMATOLOGICA, 2017, 102 : 155 - 155
  • [46] Efficacy of lenalidomide in multiple myeloma and myelodysplastic syndrome with deletion of 5q in a patient with pre-existing MGUS
    Mueller, N. Z.
    Nolte, F.
    Kreil, S.
    Hofmann, W-K
    Metzgeroth, G.
    ONKOLOGIE, 2012, 35 : 149 - 150
  • [47] Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q
    Gohring, Gudrun
    Lange, Kathrin
    Hofmann, Winfried
    Nielsen, Kirsten Vang
    Hellstrom-Lindberg, Eva
    Roy, Lydia
    Morgan, Michael
    Kreipe, Hans
    Buesche, Guntram
    Giagounidis, Aristoteles
    Schlegelberger, Brigitte
    BLOOD, 2010, 116 (21) : 18 - 18
  • [48] Elderly patients with myelodysplastic syndrome with del 5q receiving lenalidomide: two case reports with poor prognosis
    不详
    ANNALES DE BIOLOGIE CLINIQUE, 2010, 68 (02) : 248 - 253
  • [49] Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
    G Göhring
    K Lange
    W Hofmann
    K V Nielsen
    E Hellström-Lindberg
    L Roy
    M Morgan
    H Kreipe
    G Büsche
    A Giagounidis
    B Schlegelberger
    Leukemia, 2012, 26 : 356 - 358
  • [50] Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series
    Coutinho, Rita
    Costa, Dolors
    Carrio, Ana
    Munoz, Concha
    Vidal, Ana
    Belkaid, Mohammed
    Campo, Elias
    Nomdedeu, Benet
    ANNALS OF HEMATOLOGY, 2010, 89 (10) : 1069 - 1070
12345